Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous brincidofovir versus intravenous cidofovir for adenovirus infection after allogeneic hematopoietic cell transplantation
2025-521903-28-00Phase 3Authorised
- Sponsor
- SymBio Pharmaceuticals
- Start
- May 2026
- Modality
- Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in adenoviral infection and Adenovirus infection comparing Intravenous brincidofovir with Intravenous cidofovir (2 arms). Primary endpoint: Proportion of subjects with AdV virological success. Planned start May 2026; status: authorised.
02
Drugs
brincidofovircidofovir
03
Conditions
adenoviral infectionAdenovirus infection
Beyond the preview
Go deeper on 2025-521903-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521903-28-00.